492 related articles for article (PubMed ID: 15591654)
21. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
22. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.
Wesierska-Gadek J; Wandl S; Kramer MP; Pickem C; Krystof V; Hajek SB
J Cell Biochem; 2008 Dec; 105(5):1161-71. PubMed ID: 18846503
[TBL] [Abstract][Full Text] [Related]
23. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
24. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
[TBL] [Abstract][Full Text] [Related]
25. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
[TBL] [Abstract][Full Text] [Related]
26. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells.
Wojciechowski J; Horky M; Gueorguieva M; Węsierska-Gądek J
Int J Cancer; 2003 Sep; 106(4):486-495. PubMed ID: 12845642
[TBL] [Abstract][Full Text] [Related]
27. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.
Schmid G; Strosznajder JB; Wesierska-Gadek J
Mol Neurobiol; 2006 Aug; 34(1):27-50. PubMed ID: 17003520
[TBL] [Abstract][Full Text] [Related]
28. Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.
Wesierska-Gadek J; Gueorguieva M; Herbacek I; Ranftler C
Ann N Y Acad Sci; 2007 Jan; 1095():45-52. PubMed ID: 17404016
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.
Wesierska-Gadek J; Maurer M; Schmid G
J Cell Biochem; 2007 Oct; 102(3):736-47. PubMed ID: 17415788
[TBL] [Abstract][Full Text] [Related]
30. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
32. Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment.
Wesierska-Gadek J; Borza A; Walzi E; Krystof V; Maurer M; Komina O; Wandl S
J Cell Biochem; 2009 Apr; 106(5):937-55. PubMed ID: 19180585
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
34. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
[TBL] [Abstract][Full Text] [Related]
35. Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
David-Pfeuty T; Legraverend M; Ludwig O; Grierson DS
Int J Oncol; 2010 Apr; 36(4):873-81. PubMed ID: 20198331
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
37. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
[TBL] [Abstract][Full Text] [Related]
38. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
Gritsch D; Maurer M; Zulehner N; Wesierska-Gadek J
J Exp Ther Oncol; 2011; 9(1):37-45. PubMed ID: 21275264
[TBL] [Abstract][Full Text] [Related]
40. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
